Novocure Q4 Misses Street View, New Data Shows TTFields Initiates Downstream Anti-Tumor Response

 A new study published in the Journal of Clinical Investigation (JCI) finds treatment with Novocure Ltd's 

NVCR +0.16%

 (Get Free Alerts for NVCR) Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response.

• Preclinical research has shown that TTFields may induce a pro-inflammatory and broader immunological effect on tumor cells. 
• Data demonstrated that treatment with TTFields directly disrupted the nuclear envelope of glioblastoma (GBM) tumor cells, leading to leakage of DNA that activates the cGAS/STING and AIM2 signaling pathways, driving early anti-tumor immune responses. 
• Further, a genetic signature was identified in patients treated with TTFields therapy, indicating an acquired immune response. 
• Earnings: Novocure posted Q4 sales of $133.2 million, down 7.5% Y/Y, missing the consensus of $135.42 million.
• The gross margin for the quarter was 78%.
• The Company posted an EPS loss of $(0.25), compared to the income of $0.05, missing the consensus of $(0.10).
• There were 3,587 active patients on therapy, +5% Y/Y.
• Guidance: The Company expects to achieve active patient growth between 2% to 5% in 2022, in-line with the growth rate experienced in Q4 FY21.

https://www.benzinga.com/general/biotech/22/02/25813661/novocure-q4-earnings-miss-street-view-new-data-shows-ttfields-initiates-downstream-anti-tumor-res